newsfilter
← Latest News
PR Newswire·

Sales of Leqembi® totaled 32.2 billion yen in the third quarter 2026

BRCTF
  • Eisai published preliminary global revenue for Leqembi of JPY 32.2 billion for Q3 2026.
  • BioArctic received a royalty of SEK 203.8 million from these sales.
  • The royalty amount represents an increase of approximately 74 percent compared to Q3 2025.
  • BioArctic will publish its full Q3 2026 report on November 25, 2026, at 08:00 am CET.
  • Leqembi is approved in 53 countries with regulatory reviews ongoing in six additional regions.
  • Four-week intravenous maintenance dosing is approved in nine regions including the US, Japan, China, & the UK.
  • Subcutaneous dosing with an autoinjector is approved in the US, while similar applications were approved in China & Japan in September 2026.
  • The AHEAD 3-45 Phase 3 study for preclinical Alzheimer's disease remains ongoing after fully recruiting in October 2024.
  • The Tau NexGen study for Dominantly Inherited Alzheimer's disease is ongoing with lecanemab as the backbone therapy.
  • BioArctic holds commercialization rights for lecanemab in the Nordic region through its long-term collaboration with Eisai.
  • BioArctic earns payments based on sales milestones & global royalties without incurring development costs for lecanemab.
  • BioArctic AB (publ) is a Swedish biopharma company listed on Nasdaq Stockholm focusing on neurodegenerative disease treatments.